Literature DB >> 2522758

Immunohistological features of synovitis in ankylosing spondylitis: a comparison with rheumatoid arthritis.

B L Kidd1, K Moore, M T Walters, J L Smith, M I Cawley.   

Abstract

The immunohistological features of the synovial membrane in ankylosing spondylitis, HLA-B27 associated oligoarthritis, and rheumatoid arthritis wer examined with particular reference to T lymphocyte subsets. T helper (CD4+) cells clearly outnumbered T suppressor/cytotoxic (CD8+) cells in rheumatoid arthritis, whereas both cell types were present in equal numbers in ankylosing spondylitis. A reduction of CD4+/CD45R+ suppressor/inducer cells relative to CD4+/UCHL1+ helper/inducer cells was apparent in all diagnostic groups. The observations were suggestive of disease specific inflammatory responses within synovial membrane.

Entities:  

Mesh：

Year:  1989        PMID： 2522758      PMCID： PMC1003691          DOI： 10.1136/ard.48.2.92

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  24 in total

Review 1.  Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome.

Authors:  J M Moll; I Haslock; I F Macrae; V Wright
Journal:  Medicine (Baltimore)       Date:  1974-09       Impact factor: 1.889

2.  Synovitis of recent onset. A clinicopathologic study during the first month of disease.

Authors:  H R Schumacher; R C Kitridou
Journal:  Arthritis Rheum       Date:  1972 Sep-Oct

3.  The microscopic appearance of synovial membranes in peripheral joints in ankylosing spondylitis.

Authors:  T Wagner
Journal:  Reumatologia       Date:  1970

4.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens.

Authors:  P Parham; C J Barnstable; W F Bodmer
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Histopathology of the synovial membrane of peripheral joints in ankylosing spondylitis.

Authors:  P A Revell; V Mayston
Journal:  Ann Rheum Dis       Date:  1982-12       Impact factor: 19.103

7.  Synovial inflammatory cell reaction in chronic arthritis.

Authors:  H Julkunen
Journal:  Acta Rheumatol Scand       Date:  1966

8.  In situ localization of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies.

Authors:  C J Meijer; C B de Graaff-Reitsma; G J Lafeber; A Cats
Journal:  J Rheumatol       Date:  1982 May-Jun       Impact factor: 4.666

9.  Phenotypic characterization of synovial tissue cells in situ in different types of synovitis.

Authors:  S Lindblad; L Klareskog; E Hedfors; U Forsum; C Sundström
Journal:  Arthritis Rheum       Date:  1983-11

10.  An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies.

Authors:  O Duke; G S Panayi; G Janossy; L W Poulter
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330
View more
  13 in total

1.  Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis.

Authors:  L Laloux; M C Voisin; J Allain; N Martin; L Kerboull; X Chevalier; P Claudepierre
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

2.  An investigation of T-cell subset phenotype and function in the rheumatoid synovium using in situ hybridization for IL-2 mRNA.

Authors:  C J Warren; W M Howell; M Bhambhani; M I Cawley; J L Smith
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

3.  Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases.

Authors:  R J François; L Neure; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2005-10-25       Impact factor: 19.103

4.  Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity.

Authors:  D Baeten; P Demetter; C Cuvelier; F Van Den Bosch; E Kruithof; N Van Damme; G Verbruggen; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2000-12       Impact factor: 19.103

Review 5.  Cytokines and the immunopathology of the spondyloarthropathies.

Authors:  J Braun; J Sieper
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

6.  Sparse distribution of gamma/delta T lymphocytes around human epithelial tumors predominantly infiltrated by primed/memory T cells.

Authors:  S Miescher; M Schreyer; C Barras; P Capasso; V von Fliedner
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies.

Authors:  E Toussirot; P Lafforgue; J Boucraut; P Despieds; A Schiano; D Bernard; P C Acquaviva
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

Review 8.  [Immunopathology of ankylosing spondylitis and other spondyloarthritides].

Authors:  H Appel; C Loddenkemper; J Sieper
Journal:  Z Rheumatol       Date:  2008-02       Impact factor: 1.372

9.  High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies.

Authors:  M Drouart; P Saas; M Billot; J-P Cedoz; P Tiberghien; D Wendling; E Toussirot
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

10.  Detection of IL-2 at mRNA and protein levels in synovial infiltrates from inflammatory arthropathies using biotinylated oligonucleotide probes in situ.

Authors:  W M Howell; C J Warren; N J Cook; M I Cawley; J L Smith
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.